<DOC>
	<DOCNO>NCT03078478</DOCNO>
	<brief_summary>The trial conduct Europe , North America The aim trial compare efficacy safety insulin degludec insulin glargine 300 units/mL subject type 2 diabetes mellitus inadequately treat basal insulin without oral antidiabetic drug .</brief_summary>
	<brief_title>A Trial Comparing Efficacy Safety Insulin Degludec Insulin Glargine 300 Units/mL Subjects With Type 2 Diabetes Mellitus Inadequately Treated With Basal Insulin With Without Oral Antidiabetic Drugs</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Insulin , Long-Acting</mesh_term>
	<mesh_term>Hypoglycemic Agents</mesh_term>
	<mesh_term>Insulin Glargine</mesh_term>
	<criteria>Inclusion criterion : Male female , age equal 18 year time signing informed consent . Subjects fulfil least one criterion ( For inclusion criterion aim include minimum 80 % individual previous episode hypoglycaemia ( criterion e ) . The remain subject fulfil least one criterion ad . ) : ) Experienced least one severe hypoglycaemic episode within last year ( accord ADA definition , April 2013 ( An episode require assistance another person actively administer carbohydrate , glucagon , take corrective action . Plasma glucose concentration may available event , neurological recovery follow return plasma glucose normal consider sufficient evidence event induce low plasma glucose concentration. ) . b ) Moderate chronic renal failure , define glomerular filtration rate 30 59 mL/min/1.73 m^2 per CKDEPI central laboratory analysis . c ) Hypoglycaemic symptom unawareness ( History impair autonomic response ( tremulousness , sweat , palpitation , hunger ) hypoglycaemia ) . ) Treated insulin 5 year . e ) Episode hypoglycaemia ( define symptom hypoglycaemia and/or episode low glucose measurement ( equal 70 mg/dL [ equal 3.9 mmol/L ] ) ) within last 12 week prior Visit 1 ( screen ) . Subjects diagnose ( clinically ) type 2 diabetes mellitus . Treated basal insulin ( daily twicedaily insulin ( insulin detemir ; insulin glargine 100 U/mL , biosimilar insulin glargine 100 U/mL insulin Neutral Protamine Hagedorn ) ) equal 90 day prior day screen without follow antidiabetic drug stable dos equal 90 day prior screen : ) Metformin b ) Dipeptidyl peptidase 4 inhibitor c ) Sodiumglucose cotransporter 2 inhibitor ) Alphaglucosidaseinhibitors ( acarbose ) e ) Thiazolidinediones f ) Marketed oral combination product include product list criterion 5a5e HbA1c equal 9.5 % ( 80 mmol/mol ) screen central laboratory analysis . BMI equal 45 kg/m^2 . Treatment medication indication diabetes obesity state inclusion criterion period 90 day day screen</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
</DOC>